Richard J Hawkins
CIK 1307632 · Chief Executive Officer · last filed 2026-10-01
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
SCLN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
FOSTER CITY, CA 94404-2125
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CNSY | Director | 2,450 | $0.64 | $1.6K | $0 | 1 | 2026-10-01 |
| PLUS THERAPEUTICS, INC. (PSTV) Delisted | Director | 1,529 | $3.87 | $5.9K | $25.5K | 13 | 2026-07-01 |
| SVRA | Director | 161,326 | $4.83 | $779.2K | -$205.6K | 14 | 2025-12-11 |
| LUMOS PHARMA, INC. (LUMO) Delisted | Chief Executive Officer | 0 | $4.34 | $0 | $39.3K | 12 | 2024-12-13 |
| PLUS THERAPEUTICS, INC. (CYTX) Delisted | Director | 8,435 | — | — | $0 | 15 | 2017-11-29 |
| SCICLONE PHARMACEUTICALS INC (SCLN) Delisted | Director | 0 | — | — | -$908.5K | 20 | 2017-10-16 |
Recent Filings · Page 3 of 8
77 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-04-04 | LUMOS PHARMA, INC. (LUMO) Delisted | Tax (F) | −1,522 | -$5.0K | EDGAR |
| 2023-03-06 | PLUS THERAPEUTICS, INC. (PSTV) Delisted | Buy (P) | +1 | $1.0K | EDGAR |
| 2023-02-17 | PLUS THERAPEUTICS, INC. (PSTV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-02-03 | LUMOS PHARMA, INC. (LUMO) Delisted | Mixed | +4,084 | $14.4K | EDGAR |
| 2022-12-15 | SVRA | Grant (A) | — | $0 | EDGAR |
| 2022-12-08 | SVRA | Exer (M) | +1,172 | $762 | EDGAR |
| 2022-09-23 | LUMOS PHARMA, INC. (LUMO) Delisted | Buy (P) | +2,422 | $21.4K | EDGAR |
| 2022-09-21 | LUMOS PHARMA, INC. (LUMO) Delisted | Buy (P) | +2,047 | $17.9K | EDGAR |
| 2022-04-05 | LUMOS PHARMA, INC. (LUMO) Delisted | Tax (F) | −1,466 | -$13.5K | EDGAR |
| 2022-02-03 | LUMOS PHARMA, INC. (LUMO) Delisted | Mixed | +4,327 | $43.4K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.